At the annual Miami Breast Cancer Conference, Kelly Hunt, MD, discussed the use of neoadjuvant endocrine therapy for patients with breast cancer.
IPATunity130 trial data showed that adding ipatasertib to paclitaxel did not improve PFS in patients with PIK3CA/AKT1/PTEN-altered TNBC.
True or false: Paclitaxel improved PFS and OS compared to capivasertib plus paclitaxel for metastatic triple-negative breast cancer.
True or false: PIK3CA mutations in breast cancer are not accurately detected using ctDNA versus tumor tissue.
The FDA has approved pembrolizumab combined with chemo for the treatment of locally recurrent unresectable or metastatic TNBC.
Use of hormone-modulating therapy for breast cancer was tied to a significant decrease in the number of patients diagnosed with neurodegenerative disease.
Capivasertib in combination with paclitaxel yielded longer PFS and OS in patients with metastatic TNBC, particularly those with PIK3CA/AKT1/PTEN-altered tumors.
True or false: PIK3CA mutations in breast cancer can be accurately detected using ctDNA.
True or False: In patients with previously-treated, ERBB2+, metastatic breast cancer, adding capecitabine to T-DM1 improved outcomes over T-DM1 alone.